Share this article on:

Association Between Malaria and CD4 Cell Count Decline Among Persons With HIV

Mermin, Jonathan; Lule, John R; Ekwaru, John P

JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 January 2006 - Volume 41 - Issue 1 - pp 129-130
Letters to the Editor

Centers for Disease Control and Prevention-Uganda, Global AIDS Program, Centers for Disease Control and Prevention, Uganda Virus Research Institute, Entebbe, Uganda

To the Editor:

Recent information that episodes of Plasmodium falciparum malaria are associated with an average increase of 0.25 log in HIV viral load for approximately 2 months1 supports previous findings of an association between malaria and viral load.2 It is not known whether this level and duration of increase in viral load affect HIV disease progression,3 however, because CD4 cell count measurements, markers of HIV disease progression, were not conducted at follow-up.

To examine the potential long-term effects of clinical malaria on HIV disease, we examined data collected during a 2-year cohort study in Uganda.4,5 Participants with HIV infection provided blood for CD4 cell count testing at baseline, at 5 months just before they began cotrimoxazole prophylaxis, and 1.5 years later. Participants were visited at their homes weekly. If they reported fever, we took a blood smear, and if the smear was positive for malaria, we brought treatment to the participant's home within 24 hours.

Of 449 HIV-infected persons with available CD4 cell count data for at least 2 time points and no malaria parasitemia at the time of blood draws, baseline CD4 cell counts were <200 cells/μL for 24%, 200 to 500 cells/μL for 45%, and >500 cells/μL for 31%. There were 1024 slides from fever episodes during follow-up, 112 (11%) of which were associated with parasitemia in 92 participants (22.3 episodes of malaria per 100 person-years). The mean time from malaria to the subsequent CD4 cell count was 123 days (range: 7-553 days). Malaria was associated with a more rapid decline in CD4 cell count. Adjusting for sex, age, and baseline CD4 cell count, the mean difference in CD4 cell decline per each additional malaria episode was 40.5 cells/μL per year (95% confidence interval [CI]: 13.1 to 68.0; P = 0.0038). Compared with people with no malaria episodes, the mean difference in annual CD4 cell count decline for persons with 1 episode was 5.4 (95% CI: −63 to 74) cells/μL; for persons with 2 episodes, it was 84 (95% CI: 11 to 157) cells/μL; and for persons with ≥3 episodes, it was 142 (95% CI: −26 to 311) cells/μL. The association between malaria and CD4 cell count decline was seen across all baseline CD4 strata (P = 0.18 for effect modification of baseline CD4 cell count on the relation between malaria and CD4 cell count decline). Although cotrimoxazole prophylaxis was associated with a decreased incidence of malaria, there was no interaction between prophylaxis, malaria, and CD4 cell count decline.

A possible reason for the association between malaria and CD4 cell count decline could be that people with more advanced disease at baseline were more likely to have malaria during follow-up, because CD4 cell count has previously been associated with incidence of malaria.6 We controlled for baseline CD4 cell count, however.

In our study, people with malaria were treated promptly; yet, there was still an association with CD4 cell count decline. It may be that the immune reaction to malaria persists beyond the period of acute illness and the 8 to 9 weeks of increased HIV viral load. It would be useful for additional studies to examine the effect of malaria on direct outcomes of HIV disease progression, such as morbidity and mortality. The findings that malaria is associated with increased viral load and a more rapid decrease in CD4 cell count support the importance of malaria prevention among persons with HIV, including the routine use of cotrimoxazole prophylaxis and insecticide-treated bed nets.

Jonathan Mermin

John R. Lule

John P. Ekwaru

Centers for Disease Control and Prevention-Uganda, Global AIDS Program, Centers for Disease Control and Prevention, Uganda Virus Research Institute, Entebbe, Uganda

Back to Top | Article Outline


1. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet. 2005;365:233-238.
2. Hoffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS. 1999;13:487-494.
3. Whitworth JAG, Hewitt KA. Effect of malaria on HIV-1 progression and transmission. Lancet. 2005;365:196-197.
4. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4 cell count, and HIV viral load among persons with HIV in rural Uganda. Lancet. 2004;364:1428-1434.
5. Mermin J, Lule JR, Ekwaru JP, et al. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS. 2005;19:1035-1042.
6. French N, Nakiyingi J, Lugada E, et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS. 2001;15:899-906.

Cited By:

This article has been cited 2 time(s).

Current Opinion in Infectious Diseases
HIV and malaria: interactions and implications
Slutsker, L; Marston, BJ
Current Opinion in Infectious Diseases, 20(1): 3-10.
PDF (283) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Feasibility and Effectiveness of Cotrimoxazole Prophylaxis for HIV-1-Infected Adults Attending an HIV/AIDS Clinic in Uganda
Watera, C; Todd, J; Muwonge, R; Whitworth, J; Nakiyingi-Miiro, J; Brink, A; Miiro, G; Antvelink, L; Kamali, A; French, N; Mermin, J
JAIDS Journal of Acquired Immune Deficiency Syndromes, 42(3): 373-378.
PDF (116) | CrossRef
Back to Top | Article Outline
© 2006 Lippincott Williams & Wilkins, Inc.